Overview

This trial is active, not recruiting.

Condition cancer
Sponsor Taipei Medical University WanFang Hospital
Start date August 2010
End date December 2013
Trial size 1500 participants
Trial identifier NCT01311388, 99049

Summary

The investigators want to achieve the goal of diagnosis in early phase, accurate treatment and existence for a long period in order to screen in early phase, diagnose in clinical trial, choose treatment and evaluate prognosis of cancers by establishing molecular pathology tools.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective retrospective

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: - above 20 years old - all kinds of cancer patients Exclusion Criteria: - under 20 years old - none cancer patients

Additional Information

Official title Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center
Principal investigator Wen-Ta Chiu
Description This research is going to discuss the biomarker expression of common malignant neoplasm (tumor)among Taiwanese, such as large intestine rectal cancer, breast cancer, prostate gland cancer, lung cancer, oral cancer, gastric cancer, liver cancer, cervical cancer, cancer of the womb, ovarian cancer, carcinoma of urinary bladder, kidney cancer and so on. The investigators hope to find the biomarker of common tumors among Taiwanese in order to develop the tools of tumor screening, diagnosis, treatment methods and prediction prognosis
Trial information was received from ClinicalTrials.gov and was last updated in March 2011.
Information provided to ClinicalTrials.gov by Taipei Medical University WanFang Hospital.